


Anti-Human IL-12 p35 Azide Free

PRODUCT SPECIFICATIONS

| | |
|----------------------------|--|
| Catalogue N° | 855.120.000 - 200µg / 200µl 855.120.005 - 500µg / 500µl |
| Target species | Human |
| Specificity | Recognises both natural and recombinant human IL-12 p35 + p70 |
| Clone | B-T21 |
| Application | ELISA Functional assay |
| Hybridoma | Myeloma X63/AG.8653 x Balb/c spleen cells |
| Immunisation | Recombinant human IL-12 |
| Quantity | 200µg or 500µg (Discovery Size also available please enquire) |
| Isotype | Mouse IgG1 Kappa light chain |
| Format | Phosphate-buffered saline. Sterile-filtered through 0.22 µm. Carrier and preservative free |
| Storage | Stable at +2-8°C for 12 months. For longer storage freeze aliquots. |
| Biological Activity | Inhibits IL-12 induced IFNγ synthesis on PHA activated lymphocytes |
| Synonym | IL-12p35/p70 |



ELISA quantification of IFNγ secretion by PBMC (PHA activated after 72 hours) with IL-12 (300 pg/ml) and different concentration of B-T21 or isotype control.

Discover Diaclone

With over 30 years experience and extensive expertise, we are committed to providing excellence in Monoclonal Antibody and Immunoassay development.

The expanding range of Diaclone Immunology products is specifically designed to advance research applications.

Our experience and expertise coupled to the diversity and quality of our product range makes Diaclone a clear choice to :

Fast Track Your Research

Diaclone products



6 rue Dr Jean-François-Xavier Girod
BP 1985
25020 Besançon cedex
France

Tel : +33 (0)3 81 41 38 38
Fax : +33 (0)3 81 41 36 36


Email : Info@diaclone.com


www.diaclone.com

REFERENCES

Kolanowski, S. T. H. M. et al., *Innate Immunity*,2013: 1753425913498626. -

[Pubmed link](#) 

Nagai, T. et al., *J Immunol.*,2003; 171(10): 5233-43. - [Pubmed link](#) 

Oppmann, B. et al., *Immunity*,2000; 13(5): 715-25. - [Pubmed link](#) 

BACKGROUND

IL-12 is a pleiotropic cytokine initially called cytotoxic lymphocyte maturation factor (CLMF) or natural killer cell stimulatory factor (NKSF) mainly produced by monocytes, macrophages and dendritic cells in response to bacterial products or upon interaction with activated T Cell.

IL-12 induces IFN γ production and increases proliferation and cytotoxic activity of T and NK cells. Moreover, IL-12 induces CD4⁺ polarization to the Th1 phenotype that mediates immunity against intracellular pathogens.

IL-12p70 is the biologically active form and is composed of two subunits: IL-12p35 (also named IL-12A) and IL-12p40 (also named IL-12B). The p35 subunit has homology to IL-6, while p40 has homology with IL-23. The p40 subunit has been found to be expressed in a higher excess over p70. It is present in serum and plasma as a monomer, a heterodimer with IL-12p35 (biologically active IL-12p70) or heterodimer with IL-23p19 (IL-23). The subunits are genetically unrelated and are regulated independently: IL-12p40 is produced constitutively and in excess of IL-12p35 and IL-23p19.

Several studies show that IL-12p40, in monomer or homodimer form, was able to bind to IL-12R beta-1 and seem to be antagonist to IL-12p70 and IL-23 binding.

Following these properties and the role of IL-12 in autoimmunity, IL-12p40 was described as a target in the treatment of autoimmune and systemic inflammatory diseases (Crohn's disease, Psoriasis, multiple sclerosis).

Version 12 - 05.21

For research use only